ILiAD Biotechnologies Reports First-ever Demonstration Of Protection Against B. pertussis Colonization In Phase 2b Human Challenge Study Of BPZE1 Vaccine

9/6/23 8:39:34 AM ET

Multi-Sector Companies

Miscellaneous

Get the next $NTIP alert in real time by email

Network-1 Technologies, Inc. (NYSE:NTIP), a company engaged in the acquisition, development, licensing, and monetization of intellectual property, announced today that ILiAD Biotechnologies, LLC reported the first-ever demonstration of protection against B. pertussis (whooping cough) colonization in a Phase 2b Human Challenge study of its BPZE1 vaccine.

ILiAD announced that its BPZE1 intranasal pertussis vaccine has met the primary endpoint of protection against nasopharyngeal B. pertussis colonization (p=0.03) in the Phase 2b CHAMPION-1 Study. To date, Network‑1 has invested an aggregate of $7,000,000 in ILiAD which represents approximately 6.8% of the outstanding units of ILiAD on a non-fully diluted basis.

Additional information regarding the Phase 2B Human Challenge study is contained in the press release issued by IliAD, which is available at https://www.iliadbio.com/company/news.html

Get the next $NTIP alert in real time by email

ILiAD Biotechnologies Reports First-ever Demonstration Of Protection Against B. pertussis Colonization In Phase 2b Human Challenge Study Of BPZE1 Vaccine

Chat with this insight

Recent Analyst Ratings for
$NTIP

$NTIP
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Network-1 Technologies Inc. (Amendment)

SEC Form SC 13G/A filed by Network-1 Technologies Inc. (Amendment)

SEC Form SC 13G filed by Network-1 Technologies Inc.

$NTIP
Press Releases

Fastest customizable press release news feed in the world

$NTIP
Financials

Live finance-specific insights

Network-1 Reports Third Quarter Results

Network-1 Subsidiary Receives New Patent from U.S. Patent Office Expanding Its HFT Patent Portfolio To Include 11 Issued U.S. Patents

Network-1 Subsidiary Receives New Patent from U.S. Patent Office Expanding Its HFT Patent Portfolio to Include 10 Issued U.S. Patents

Network-1 Reports Third Quarter Results

Network-1 Subsidiary Receives New Patent from U.S. Patent Office Expanding Its HFT Patent Portfolio To Include 11 Issued U.S. Patents

Network-1 Subsidiary Receives New Patent from U.S. Patent Office Expanding Its HFT Patent Portfolio to Include 10 Issued U.S. Patents

$NTIP
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Mahan Robert Michael was granted 25,000 shares (SEC Form 4)

Horowitz Corey M converted options into 75,000 shares and covered exercise/tax liability with 23,505 shares, increasing direct ownership by 1% to 3,983,954 units (SEC Form 4)

Harizman Niv was granted 15,000 shares, increasing direct ownership by 5% to 317,235 units (SEC Form 4)

$NTIP
SEC Filings

Network-1 Technologies Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

Network-1 Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Network-1 Technologies Inc.

$NTIP
Market Insights

Live Market Insights

Network-1 Technologies Q1 EPS $(0.04) Down From $(0.03) YoY

Network-1 Receives New Patent From U.S. Patent Office Expanding Ots M2M/IoT Patent Portfolio To 51 Patents Worldwide